Advanced Biomed (NASDAQ:ADVB) Raised to “Hold” at Wall Street Zen

Advanced Biomed (NASDAQ:ADVB) was upgraded by equities research analysts at Wall Street Zen to a “hold” rating in a report released on Saturday.

Separately, Weiss Ratings raised shares of Advanced Biomed from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 23rd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Advanced Biomed Stock Performance

ADVB stock opened at $8.14 on Friday. The firm has a 50 day moving average of $7.24 and a 200-day moving average of $5.67. Advanced Biomed has a 12 month low of $3.61 and a 12 month high of $24.23. The firm has a market capitalization of $13.43 million, a P/E ratio of 1.69 and a beta of -0.41.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Advanced Biomed stock. BlackRock Inc. purchased a new stake in shares of Advanced Biomed Inc. (NASDAQ:ADVB) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 59,944 shares of the company’s stock, valued at approximately $186,000. BlackRock Inc. owned about 3.63% of Advanced Biomed as of its most recent SEC filing.

About Advanced Biomed

Our Mission We are committed to the application research of integrating semiconductor technology and biotechnology. Through the enrichment, capture, and identification of circulating tumor cells and related tumor marker cells in the field of liquid biopsy, we aim to provide cancer patients with rapid and affordable assay products and services. These services include early screening and detection, diagnosis and staging, treatment selection, and patient outcome interventions for cancer. We are a holding company incorporated in the State of Nevada.